

Neurotech to Present at E&P Small Cap Healthcare Conference

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces an upcoming presentation by Dr Thomas Duthy, Executive Director at the inaugural E&P Small Cap Healthcare Conference in Sydney on 7 September 2022.

A copy of the presentation is attached.

E&P Financial Group is a financial services business with a history spanning more than 30 years with over 8,000 wealth advice clients, >\$21 billion in funds under advice, >160 institutional clients and \$6.2 billion of assets across its different strategies.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders that improve quality of life. Neurotech is currently conducting a world-first clinical trial to assess the potential application of NTI164 for the treatment of Autism Spectrum Disorder (ASD). Results of Phase I/II indicated that 93% of participants had notable improvements relating to the severity of illness with no serious side effects. The next step will be initiation of Phase II/III of the trial to further assess the long-term safety and efficacy of NTI164, with the potential to lead to drug registration. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.



Improving Lives



E&P Small Cap Healthcare Conference

Dr Tom Duthy
Executive Director

7 September 2022

Disclaimer



IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.


Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Neurotech is a biopharmaceutical drug company focused on the development & commercialisation of neurological solutions that improve quality of life.



Exclusive worldwide
licence



Extensive preclinical
studies completed



World's first whole plant
extract cannabis clinical
study (Phase I/II)



PCT Patents lodged



Potential for NTI164
to treat neurological
disorders



Neurotech's Mente
device & therapy

Capital Structure

\$0.105

Share price
(as at 1st September 2022)

~\$73M

**Market
capitalisation**

~\$1.9M

Cash at bank*

697M

Share on issue

143M[^]

Options/rights

~\$2.6M

**R&D Investment
in FY22**

*as at 30 June 2022

[^]Options are comprised at various strike prices between \$0.005 to \$0.16 as at 1 September 2022

In addition to the above issued capital the Company has agreed to issue 35 million adviser options, 30 million director options and 33 million licensor shares, subject to shareholder approval

What makes NTI164 different?

CBD/THC

vs

NTI164

- ✗ CBDA
- ✗ Rare Cannabinoids
- ✗ Full Plant Extract
- ✗ Entourage Effect
- ✗ Patent protected composition

- ✓ High CBDA
- ✓ Rarer Cannabinoids: CBC, CBDP, CBDB, CBN, CBG
- ✓ Naturally <0.3% THC
- ✓ >4% Terpenes
- ✓ Composition of matter patent protection



Preclinical evidence from NTI164

Preclinical studies demonstrated:

- Reduction in brain cell inflammation (up to 60%)
- Increase in overall brain cell health and viability (in the absence of toxic insult up to 80%)
- Increase in mitochondrial viability and output (in the presence of toxic insult up to 60%)
- Significant suppression of neuro-markers linked to MS (GM-CSF < 40% and TNF-alpha < 30%)
- Multi-functional Mode of Action | neuro-protection, neuro-modulation and neuro-regulation



Why target Autism Spectrum Disorders (ASD)?

PREVALENCE OF ASD
~1 in 44 children
in the US¹

Market

ASD is a serious
neuro inflammatory
developmental disorder
that impairs the ability to
communicate and interact

- Common symptoms include; behavioural issues, agitation, repetitive movements, inability to focus & compulsive neurological patterns



RISPERIDONE
US\$5.6b²



**US ANNUAL
SALES US\$2.1b³**
Ritalin and Concerta
Active ingredient Methylphenidate

Current Treatment

Huge unmet medical need -
patients need better treatment

- Current drugs have numerous side effects; weight gain, breast tissue development, nausea, dry mouth, anxiety, irritability, insomnia, stomach pain & movement disorders

**TREATMENT
MARKET SIZE
US\$1.85b⁴**

Trials

NTI has completed world first
trial using whole plant (low THC)
medicinal cannabis strain in
children with ASD



NTI164 Phase I/II Trials

The Program

First in human Phase I/II ASD paediatric study (S8)

Commenced in May 2021 at Monash Children's Hospital led by A/Prof. Michael Fahey

Open label – single group

14 patients from 8 to 17yo, Level II and III Autism Spectrum Disorder

Dose regime assessments

5mg/kg, 10mg/kg, 15mg/kg and 20mg/kg

2,250 Assessment points

Parameters Anxiety, Participation, Irritability, Hyperactivity, Mood and Self-stimulation

Data Released
8 July 2022

NTI164 Phase I/II Trials

Outcomes (1)

93% of patients showed improvement

Global Improvement

64% of patients "much improved"

29% of patients "minimally improved"

7% of patients "no change"

Therapeutic Effect (Efficacy Index)

2 patients Therapeutic Index Score of 2

Vast Improvement complete or near remission of all symptoms

10 patients Therapeutic Index Score of 5 & 6

Decided improvement" – Partial remission of symptoms

No "washout" period

Due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians

**NTI164 measures favourably when compared to other recently completed
CBD and/or THC paediatric studies^{1,2}**

¹ Thomas, M. & Frampton, C., (2022) HOPE® 1 demonstrates improvements in Clinical Global Impression (CGI) in patients with Autism Spectrum Disorder. https://zeliratx.com/wp-content/uploads/2022/04/ZEL040-White-Paper_Hope_FA.pdf


² Shani Poleg, et al (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro- Psychopharmacology and Biological Psychiatry. <https://www.sciencedirect.com/science/article/abs/pii/S0278584618304445>

Outcomes (2)

Severity of illness reduced by 0.8 / 18% at 28 days

Average rating for the severity of illness at baseline was **4.4**

Average rating for the severity of illness at 28 Days of treatment with NTI164 was **3.6**



NTI164 Phase I/II Trials

NTI164 was well-tolerated

No serious adverse events recorded

Across all doses (5, 10, 15 and 20 mg/kg)

NTI164 shows promise compared to other current treatments

Risperidone

Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including:

- Weight gain,
- Sedation and
- Hormonal imbalance

***Chief Investigator Professor Fahey,
Monash Children's Hospital said,***

“I am very encouraged with these results. We have designed a rigorous study on all fronts to assess the potential application of NTI164 for the treatment of ASD. We are encouraged by the efficacy shown by NTI164 in this trial and we are looking forward to the extension of this trial, in addition to the planned initiation of a Phase II/III trial, to further assess the long-term safety and efficacy of NTI164 with the potential to lead to drug registration.”

Pipeline (Pro-Forma 1 Jan 2023)

Pre-Clinical

NTI164

Combination Therapies
Prednisone, Diclofenac, Other

Other Licensed
Strains

Phase I/II

NTI164
Cerebral Palsy

NTI164
New Paediatric Disorder

NTI164
ASD
(54 week open label extension)

Phase II/III

NTI164
ASD

Selected Market Sizes

**AUTISM
SPECTRUM
DISORDER**
US\$2.3b¹

Phase I/II completed

Phase II/III due to
commence Q3 2022

ADHD
US\$21b²

Future Target

**CEREBRAL
PALSY**
US\$4.4b³

Phase I/II due to
commence Q1 2023

Strong Patent Position

Neurotech has lodged two strategic provisional patent applications with IP Australia to underpin future worldwide commercialisation in Neurological applications and has completed international prior art search.

Composition

Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of ‘rarer’ cannabinoids:
CBDA, CBC, CBDP, CBDB & CBN

Lodged Oct 2021

Combination

The application, formulation and use of NTI164

Lodged Oct 2021

Pathways to Commercialisation

The anti-inflammatory properties NTL strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation:

Pharmaceutical

- Orphan Indications
- Paediatric Focus
- FDA/TGA new drug registration
- Huge potential upside
- Partnering & Licensing Opportunities

**GW Pharmaceuticals US\$7.2B
Acquisition by Jazz Pharmaceuticals**


Neurotech vs Cannabis ASX Peers

	Zelira Therapeutics Ltd	Neurotech International Ltd	Emyria Ltd	Little Green Pharma Ltd	Incannex Healthcare Ltd
Ticker	ZLD	NTI	EMD	LGP	IHL
Market Cap	A\$15M	A\$73M	A\$74M	A\$79M	A\$358M
Properties	CBD, CBD+THC	CBD-A, CBG, CBN, CBN-B, CBD-P	Low and High dose CBD	CBD, THC, TCH+CBD	CBD
Stage	Commercial	Phase II/III Clinical	Clinical	Clinical, Commercial	Clinical
Indication(s)	Insomnia & Autism	Autism, Cerebral Palsy, Other paediatric orphan disorders	Psychological distress, IBS	N/A	OSA, IBS, Lung Inflammation, Rheumatoid Arthritis, Concussion, Anxiety
Source	Website	Internal	Website	Website	Website


Neurotech vs Orphan Disease ASX Peers

	Neurotech International Ltd	Neuren Pharmaceuticals Ltd	Prescient Therapeutics Ltd	Paradigm Pharmaceuticals Ltd	Race Oncology Ltd
Ticker	NTI	NEU	PTX	PAR	RAC
Market Cap	A\$73M	A\$769M	A\$115M	A\$340M	A\$319M
Stage	Phase II/III Clinical	Phase III / NDA	Phase Ib	Phase III	Phase II
Treatments	Autism, Cerebral Palsy, Other paediatric orphan disorders	Rett Syndrome, Fragile X, Other Neurological Orphan Syndromes	Oncology	Osteoarthritis, MPS, ARDS	Oncology
Source	Internal	Website	Website	Website	Website

NTI164 Development Program Timeline



Why Invest



**Experienced
board and
management**



**Unique
biopharmaceutical
cannabinoid drug
platform**



**Clinical programs
underway
targeting pivotal,
unmet paediatric
orphan needs**



**Significant
near term
milestones
& newsflow**





Neurotech

International

Contact Details

Dr Tom Duthy
Executive Director
td@neurotechinternational.com
+61 402 493 727

Media:
Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 (0)431 636 033

www.neurotechinternational.com
www.mentetech.com

Neurotech International Limited (ASX: NTI)